Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brenda Sandburg

New York, NY
Brenda Sandburg is a senior writer who covers legal issues and FDA regulatory policy, with a particular focus on patents, biosimilars, and government investigations. She spent 10 years writing for legal publications between stints at The Pink Sheet and blends these experiences to provide in-depth analysis of events. An aspiring photographer, she enjoys taking photos to accompany news stories.
Advertisement
Set Alert for Articles By Brenda Sandburg

Latest From Brenda Sandburg

Walgreens Agrees To Oversight, Settles Insulin Pen Overdispensing, Discount Pricing Claims

DOJ settlements totaling $269m resolve two False Claims Act cases; company enters corporate integrity agreement requiring independent review organization to assess claims.

Legal Issues Medicaid

Sale of Invention May Block Its Patenting Even If Details Are Not Disclosed, Supreme Court Concludes

America Invents Act did not alter the meaning of "on sale," unanimous court finds, so a confidential sale can qualify as prior art.

Legal Issues Intellectual Property

Medicare Part D Payment Model Gives Health Plans More Incentives To Negotiate Lower Drug Prices

Participating plans to share in savings if they stay below spending target for Part D catastrophic phase and repay 10% of any excess spending; CMS also updates its VBID model.
Medicare Pricing Debate

US Federal Courts Can Operate Until Jan. 25; Patent Office Faces Eminent Closure Under Shutdown

Federal courts and USPTO will soon run out of funds that have allowed them to continue normal operations; pending ANDAs to get same filing date, which could lead to FDA legal challenges.
Legal Issues Intellectual Property

Bristol-Celgene: Congressional Reps Want Assurance Merger Will Not Increase Prices

Reps. Welch and Rooney urge FTC and DOJ to condition their approval of the merger on inclusion of a pricing provision.

Pricing Debate M & A

Co-Pay Vouchers May Not Be Enough To Boost Patient Adherence To Blood Thinners

Acute MI patients who received voucher had 3.3% increase in persistence with clopidogrel or ticagrelor, but no significant reduction in major adverse cardiovascular events, ARTEMIS study finds.

Policy Cardiovascular
See All
Advertisement
UsernamePublicRestriction

Register